Audit: QRS - Oregano Oil for Health & Longevity
Audit conducted on 22/08/2026 04:48 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER lines 377/385/389; time-to-effect to ER line 440; benefits/risks to the ER tier headings; monitoring rows to the ER table at lines 476–484. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “laboratory signs it may speed liver drug clearance” mirrors ER line 517; speculative-tier risks retain the ER’s hedged framing via the tier label. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications keep absolute force (“Pregnancy at any gestational stage”); the “unless levels are monitored” condition on narrow-therapeutic-index drugs is preserved. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from ER Key Interactions & Contraindications; risks only from Potential Risks & Side Effects; no modifying-factor content is promoted. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names appear in the QRS; “St John’s wort” is an ER-sourced comparator (ER line 337). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Only generic ER-sourced references (“the parasite study”, “the Helicobacter pylori series”, “the only formal safety trial”) appear. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Reserved, uncertainty-forward framing matching the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds throughout; framing enables an informed decision rather than discouraging one. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as evidence and parameters, not as orders to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “you should”, “consult your doctor” phrasing outside the fixed template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Monitoring cadence uses passive reporting (“tolerability reviewed at one week”); no recommend/advise verbs. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Remaining technical tokens (CYP3A4, UGT1A9, Los Angeles grade) are ER bold labels required verbatim by 4.2. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier items reduced to bare ER headings; gate items stripped of rationale. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional monitoring ranges and carvacrol-standardisation detail assume a proactive optimiser. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nine-marker monitoring panel and split dosing with meal timing assume high willingness to comply. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content depth and biomarker specificity exceed general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance foregrounds the enzyme-induction and product-quality problems that matter most to a supplement-stacking audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Uses “delayed biological ageing”; the string “anti-aging” does not occur. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Body uses “Gastrointestinal burning, pain and nausea”; the plainer At-A-Glance register is mandated by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All verified verbatim at lines 440, 477, 519, 539, 553, 576, 595, 599–601, 714 and the four tier labels in each tiered card. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 67 named spans present covering header, at-a-glance, 3 action sets, 3 time sets, 4 benefit tiers, both gates, 4 risk tiers, 9 marker triplets, cadence and 6 qualitative items. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Template-only elements (website="evidence_review", website="full_review", website="audit") and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; every mapped ER section carries content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard oral regimen”, “Best time of day”, “Single versus split dosing” match ER lines 377/385/389; gate labels match the ER interaction bullets. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring marker names are verbatim from the ER table; time-to-effect labels restate the ER’s own three named endpoints at line 440. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Grep confirms no emoji characters; the ER’s “⚠️ Conflicted” markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: tier cards collapse ER headings into single semicolon-joined lines, gate items are stripped to the key fact, protocol cells compress multi-clause ER bullets. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the title text on line 2 precedes the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no duplicate metadata appears in head or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: oregano_oil_2026-0822-0231_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0822-0410. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk exactly. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Oregano Oil for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Oregano Oil for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/22/2026”, correct for creation date 2026-0822-0410. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the fixed template subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER lines 515–519 into laboratory-versus-human evidence, then the four countervailing problems. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Laboratory killing (ER 515), uncontrolled human studies (515), burning/irritation (517), St John’s wort comparison (517), product-potency failure (517). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “gut organisms”, “liver drug clearance”, “claimed potency” are lay-accessible. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Only the generic “a few small studies, mostly without comparison groups”. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers, ratios or intervals appear. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Maps to the “Populations who should avoid Oregano Oil” list at ER lines 347–353. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements at lines 542–548. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER’s “whether for bleeding risk or anaesthetic drug interference” and “until the deficiency is corrected” are trimmed to the key fact; no dashes carry trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “Los Angeles grade C or D”, “ferritin below 30 ng/mL”, “under 2 years / under 12 years”, “Within 14 days” and the Lamiaceae species list are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in its contraindication bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names seven such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Maps one-to-one to the eleven interaction bullets at ER lines 323–343. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eleven ER interaction bullets appear; none duplicates a contraindication entry, which are population-based rather than drug-class-based. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven discrete <li> elements at lines 556–566. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “caution;”/”monitor;” rationale sentences and mitigation advice are all stripped; ER em-dashes are normalised to parentheses or a colon. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example drug list is retained in full, including the CYP3A4, CYP1A2, CYP2A6, UGT1A9, anticoagulant and glucose-lowering botanical lists. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eleven such interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol bullets at lines 377, 385 and 389. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose/standardisation, timing, and dosing pattern are the three aspects that apply irrespective of target condition. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains thirteen bullets; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive ER-derived content; no placeholder remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Protozoa clearance, Helicobacter pylori clearance and symptom change are the only three the ER supplies (line 440). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Objective organism clearance (the ER’s Low-tier benefit) precedes the unranked subjective symptom change; the parasite result carries the stronger ER magnitude figure. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; values “6 weeks”, “45–60 days” and “Days to two weeks” match ER line 440. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect data, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every entry restates an ER Expected Benefits sub-heading from lines 153–213. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 521–532. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; all **Magnitude:** paragraphs and study attributions are omitted. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven entries restate ER sub-headings from lines 237–301. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 578–589. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | ER qualifiers such as “During Sustained Carvacrol Dosing” are dropped since the tier already encodes evidence strength. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows map one-to-one to the ER Monitoring Protocol & Defining Success table at lines 476–484. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers present, with targets and rationale carried across faithfully. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 708 captures baseline, one week, four weeks, end of course and 6–12 month intervals from ER lines 470–472 and 484. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the qualitative-marker list at ER lines 488–493. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present and carried verbatim. |
Issues 22/08/2026 04:48
Pass rate 100.00%. No issues found.
Issues 22/08/2026 04:41
- 1.2 / 1.3 — At-A-Glance drops ER hedges: [at_a_glance] (line 433) states “a liver drug-clearing effect rivalling St John’s wort” as established fact, whereas ER line 517 says “laboratory evidence that it may speed up the liver’s drug-clearing machinery to a degree comparable with St John’s wort”; it also converts “most products tested” (ER line 517) into an unqualified “products”, and “mostly uncontrolled studies” (ER line 515) into an unqualified “studies without comparison groups”.
Fixes 22/08/2026 04:41
- 1.2 / 1.3 — At-A-Glance hedges restored: Rewrote [at_a_glance] (line 433) to carry the ER’s own qualifiers: “a liver drug-clearing effect rivalling St John’s wort” became “laboratory signs it may speed liver drug clearance like St John’s wort”, “studies without comparison groups” became “studies, mostly without comparison groups”, and “products containing far less active compound than claimed” became “most tested products far below their claimed potency”. The rewrite stays within the 60-word budget of item 7.2.
Issues 22/08/2026 04:32
- 4.2 / 4.3 — ER bold labels dropped from two interactions: QRS line 564 renders ER “Supplements with additive effects — blood-glucose-lowering botanicals (…)” (ER line 339) as “Blood-glucose-lowering botanicals (…)”, and QRS line 566 renders ER “Other interventions — antibiotic courses and elemental diet for bacterial overgrowth” (ER line 343) as “Antibiotic courses and elemental diet for bacterial overgrowth”, abbreviating away the ER’s label in both cases.
Fixes 22/08/2026 04:32
- 4.2 / 4.3 — ER bold labels restored on two interactions: In the Key Interactions gate, “Blood-glucose-lowering botanicals (berberine, bitter melon, chromium, cinnamon extract)” became “Supplements with additive effects: blood-glucose-lowering botanicals (berberine, bitter melon, chromium, cinnamon extract)”, and “Antibiotic courses and elemental diet for bacterial overgrowth” became “Other interventions: antibiotic courses and elemental diet for bacterial overgrowth”, so both items now carry the ER’s own bold label ahead of the content.
Issues 22/08/2026 04:24
- 12.3 — Qualifier and study detail in Benefits: [benefits_low] (line 528) keeps the qualifier “modest” and [benefits_speculative] (line 531) keeps the study detail “in laboratory models”, both redundant against the tier label.
- 13.3 — Dosing qualifier in Risks: [risks_low] (line 585) keeps “during sustained carvacrol dosing”, a dosing qualifier that the Low tier already implies.
Fixes 22/08/2026 04:24
- 12.3 — Qualifier and study detail in Benefits: Removed “modest” from “modest improvement in high-density lipoprotein cholesterol” in [benefits_low], and “in laboratory models” from “antiviral activity in laboratory models” in [benefits_speculative].
- 13.3 — Dosing qualifier in Risks: Replaced “falls in iron status and HDL during sustained carvacrol dosing” with “falls in iron status and HDL cholesterol” in [risks_low].
Issues 22/08/2026 04:16
- 2.5 / 2.6 / 2.9 — Imperative advises the reader: [action_2_sub] at line 461 ends with “avoid within three hours of bedtime”, an imperative that gives guidance and addresses the reader rather than presenting the ER’s finding.
- 11.4 — Tautological time-to-effect sub: [time_3_sub] at line 511 reads “The reported window for gastrointestinal symptom change”, a restatement of [time_3_label] that carries no additional ER-derived information.
Fixes 22/08/2026 04:16
- 2.5 / 2.6 / 2.9 — Imperative advises the reader: Replaced the imperative in [action_2_sub] with a neutral statement, from “avoid within three hours of bedtime” to “not within three hours of bedtime”.
- 11.4 — Tautological time-to-effect sub: Replaced [time_3_sub] “The reported window for gastrointestinal symptom change” with “Symptom impression alone does not confirm organism clearance”, drawn from the ER’s Discontinuation & Cycling section.